Nerandomilast
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Nerandomilast (Jascayd) for idiopathic pulmonary fibrosis.
Journal: The Medical letter on drugs and therapeutics
Published: December 15, 2025
Nerandomilast.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: December 02, 2025
Nerandomilast as the first PDE4B-selective therapy in idiopathic pulmonary fibrosis.
Journal: Trends in pharmacological sciences
Published: October 28, 2025
Efficacy and Safety of Nerandomilast in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Journal: American journal of therapeutics
Published: October 21, 2025
Jascayd (nerandomilast): a novel PDE4B inhibitor for idiopathic pulmonary fibrosis.
Journal: Annals of medicine and surgery (2012)
Published: October 17, 2025
Nerandomilast in Patients with Pulmonary Fibrosis.
Journal: The New England journal of medicine
Published: October 01, 2025
Nerandomilast in Patients with Pulmonary Fibrosis. Reply.
Journal: The New England journal of medicine
Published: October 01, 2025
Nerandomilast in Patients with Pulmonary Fibrosis.
Journal: The New England journal of medicine
Published: October 01, 2025
Tweaking the complex fibrogenic role of lymphocytes in IPF.
Journal: Tuberculosis and respiratory diseases
Published: September 29, 2025
PDE4-Selective Inhibition in Chronic Obstructive Pulmonary Disease and Pulmonary Fibrosis: Different Agents or Different Targets?
Journal: Life (Basel, Switzerland)
Published: September 07, 2025
Rethinking idiopathic pulmonary fibrosis management: clinical impact of nerandomilast as a new therapeutic agent.
Journal: Annals of medicine and surgery (2012)
Published: September 05, 2025
Nerandomilast slows progression of pulmonary fibrosis.
Journal: Nature reviews. Rheumatology
Published: July 08, 2025
Last Updated: 02/24/2026